CN113354703B - Rare earth metal-based enzyme response type probe and preparation method and application thereof - Google Patents
Rare earth metal-based enzyme response type probe and preparation method and application thereof Download PDFInfo
- Publication number
- CN113354703B CN113354703B CN202010140295.8A CN202010140295A CN113354703B CN 113354703 B CN113354703 B CN 113354703B CN 202010140295 A CN202010140295 A CN 202010140295A CN 113354703 B CN113354703 B CN 113354703B
- Authority
- CN
- China
- Prior art keywords
- rare earth
- solution
- alkaline phosphatase
- probe
- earth metal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000523 sample Substances 0.000 title claims abstract description 82
- 229910052761 rare earth metal Inorganic materials 0.000 title claims abstract description 80
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 35
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 35
- 150000002910 rare earth metals Chemical class 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000004044 response Effects 0.000 title claims abstract description 15
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims abstract description 61
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims abstract description 61
- 238000001514 detection method Methods 0.000 claims abstract description 33
- 150000002500 ions Chemical class 0.000 claims abstract description 30
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 14
- 238000002156 mixing Methods 0.000 claims abstract description 10
- 239000000243 solution Substances 0.000 claims description 55
- -1 rare earth metal salts Chemical class 0.000 claims description 49
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 18
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 17
- 239000007853 buffer solution Substances 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 239000000872 buffer Substances 0.000 claims description 10
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 claims description 6
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 claims description 6
- QGWNDRXFNXRZMB-UUOKFMHZSA-N GDP Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O QGWNDRXFNXRZMB-UUOKFMHZSA-N 0.000 claims description 6
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 claims description 6
- 229910052771 Terbium Inorganic materials 0.000 claims description 6
- QGWNDRXFNXRZMB-UHFFFAOYSA-N guanidine diphosphate Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O QGWNDRXFNXRZMB-UHFFFAOYSA-N 0.000 claims description 6
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 claims description 6
- 235000013928 guanylic acid Nutrition 0.000 claims description 6
- 229940058020 2-amino-2-methyl-1-propanol Drugs 0.000 claims description 4
- 229910052684 Cerium Inorganic materials 0.000 claims description 4
- 229910002651 NO3 Inorganic materials 0.000 claims description 4
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 3
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate group Chemical group [N+](=O)([O-])[O-] NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 3
- 230000010355 oscillation Effects 0.000 claims description 3
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 2
- CWGFSQJQIHRAAE-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol tetrahydrochloride Chemical compound Cl.Cl.Cl.Cl.OCC(N)(CO)CO CWGFSQJQIHRAAE-UHFFFAOYSA-N 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 230000008901 benefit Effects 0.000 abstract description 6
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 230000005540 biological transmission Effects 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 2
- 238000004220 aggregation Methods 0.000 abstract 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 229940088598 enzyme Drugs 0.000 description 27
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 11
- 239000011259 mixed solution Substances 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000000171 quenching effect Effects 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- RQDRUXKVBVMDGG-UHFFFAOYSA-N cerium erbium Chemical compound [Ce][Er] RQDRUXKVBVMDGG-UHFFFAOYSA-N 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000012921 fluorescence analysis Methods 0.000 description 4
- HQWUQSSKOBTIHZ-UHFFFAOYSA-N gadolinium terbium Chemical compound [Gd][Tb] HQWUQSSKOBTIHZ-UHFFFAOYSA-N 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002096 quantum dot Substances 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- GCAAQROFKRZNKT-UHFFFAOYSA-N [Tb].[Ce] Chemical compound [Tb].[Ce] GCAAQROFKRZNKT-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 150000004683 dihydrates Chemical class 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 150000004687 hexahydrates Chemical class 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- 150000004686 pentahydrates Chemical class 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 150000004685 tetrahydrates Chemical class 0.000 description 3
- 150000004684 trihydrates Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- LDDMACCNBZAMSG-BDVNFPICSA-N (2r,3r,4s,5r)-3,4,5,6-tetrahydroxy-2-(methylamino)hexanal Chemical compound CN[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO LDDMACCNBZAMSG-BDVNFPICSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229910052692 Dysprosium Inorganic materials 0.000 description 2
- 229910052691 Erbium Inorganic materials 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- 229910052688 Gadolinium Inorganic materials 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 229910052689 Holmium Inorganic materials 0.000 description 2
- 229910052765 Lutetium Inorganic materials 0.000 description 2
- 229910052779 Neodymium Inorganic materials 0.000 description 2
- 229910052777 Praseodymium Inorganic materials 0.000 description 2
- 229910052773 Promethium Inorganic materials 0.000 description 2
- 229910052772 Samarium Inorganic materials 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 229910052775 Thulium Inorganic materials 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 229910052769 Ytterbium Inorganic materials 0.000 description 2
- SSCCKHJUOFTPEX-UHFFFAOYSA-N [Ce].[Nd] Chemical compound [Ce].[Nd] SSCCKHJUOFTPEX-UHFFFAOYSA-N 0.000 description 2
- HLLGEDDSJXFQEL-UHFFFAOYSA-N [Ce].[Yb].[Er] Chemical compound [Ce].[Yb].[Er] HLLGEDDSJXFQEL-UHFFFAOYSA-N 0.000 description 2
- XYVGZBPDHPUFKY-UHFFFAOYSA-N [Dy].[Ce] Chemical compound [Dy].[Ce] XYVGZBPDHPUFKY-UHFFFAOYSA-N 0.000 description 2
- KNXGUSVYMKEOHC-UHFFFAOYSA-N [Dy].[Gd] Chemical compound [Dy].[Gd] KNXGUSVYMKEOHC-UHFFFAOYSA-N 0.000 description 2
- IZCUOLNYELHOEC-UHFFFAOYSA-N [Eu].[Ce] Chemical compound [Eu].[Ce] IZCUOLNYELHOEC-UHFFFAOYSA-N 0.000 description 2
- VJNBQNKBLZXMQD-UHFFFAOYSA-N [Eu].[Tb] Chemical compound [Eu].[Tb] VJNBQNKBLZXMQD-UHFFFAOYSA-N 0.000 description 2
- VXXHJRBHKGKRGB-UHFFFAOYSA-N [Gd].[Ce] Chemical compound [Gd].[Ce] VXXHJRBHKGKRGB-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 2
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
- MDFCXYVJUZMYCJ-UHFFFAOYSA-N europium gadolinium Chemical compound [Eu][Gd] MDFCXYVJUZMYCJ-UHFFFAOYSA-N 0.000 description 2
- SFIIJZDYEUGFLB-UHFFFAOYSA-N europium gadolinium terbium Chemical compound [Eu][Tb][Gd] SFIIJZDYEUGFLB-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002189 fluorescence spectrum Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 150000004688 heptahydrates Chemical class 0.000 description 2
- 231100000086 high toxicity Toxicity 0.000 description 2
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 2
- 229910052746 lanthanum Inorganic materials 0.000 description 2
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 2
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000012621 metal-organic framework Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical compound CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 2
- QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 description 2
- PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- VQMWBBYLQSCNPO-UHFFFAOYSA-N promethium atom Chemical compound [Pm] VQMWBBYLQSCNPO-UHFFFAOYSA-N 0.000 description 2
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 2
- 229910052706 scandium Inorganic materials 0.000 description 2
- SIXSYDAISGFNSX-UHFFFAOYSA-N scandium atom Chemical compound [Sc] SIXSYDAISGFNSX-UHFFFAOYSA-N 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- UBORTCNDUKBEOP-UHFFFAOYSA-N L-xanthosine Natural products OC1C(O)C(CO)OC1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 1
- UBORTCNDUKBEOP-HAVMAKPUSA-N Xanthosine Natural products O[C@@H]1[C@H](O)[C@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-HAVMAKPUSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000001748 luminescence spectrum Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000013379 physicochemical characterization Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000002165 resonance energy transfer Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 description 1
- FRNOGLGSGLTDKL-UHFFFAOYSA-N thulium atom Chemical compound [Tm] FRNOGLGSGLTDKL-UHFFFAOYSA-N 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- UBORTCNDUKBEOP-UUOKFMHZSA-N xanthosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC(=O)NC2=O)=C2N=C1 UBORTCNDUKBEOP-UUOKFMHZSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/18—Metal complexes
- C09K2211/182—Metal complexes of the rare earth metals, i.e. Sc, Y or lanthanide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N2021/6417—Spectrofluorimetric devices
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6432—Quenching
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Optics & Photonics (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Manufacturing & Machinery (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Composite Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses an enzyme response type probe based on rare earth fluorescence resonance energy transfer, a preparation method thereof and application thereof in alkaline phosphatase detection. The enzyme response type probe utilizes supermolecule self-aggregation of rare earth sensitized ions, rare earth activated ions and phospholipid molecules, effectively shortens the energy transmission distance between the rare earth sensitized ions and the activated ions, successfully constructs the nano probe with good fluorescence characteristic, and realizes the specificity and high sensitivity detection of alkaline phosphatase. The enzyme response type probe provided by the invention is simple and quick to prepare, safe and nontoxic, and can effectively avoid interference in a biological complex system. The detection process can realize the detection of the concentration of alkaline phosphatase in serum or whole blood by simply mixing the nano probe with a sample to be detected, has the advantages of simplicity, sensitivity, good specificity, economy, practicability and the like, and provides a simple and efficient novel method and corresponding technical support for the detection of alkaline phosphatase in a complex system.
Description
Technical Field
The invention relates to the technical field of biological detection, in particular to an enzyme response type probe based on rare earth metal, a preparation method and application thereof.
Background
Enzymes are catalysts of organism metabolism and play an important role in maintaining the normal operation of various biochemical and physiological reactions of organisms. With the further knowledge of enzymes, biological enzymes have been found to be closely related to cellular activity, pathological reactions, disease occurrence, etc., and most of the disease occurrence is related to enzyme deficiency or synthesis failure. Therefore, the enzyme has an indication effect in disease prevention, early diagnosis, drug reaction and the like. Alkaline phosphatase is an important enzyme disease marker, and is closely related to the occurrence and development of serious diseases such as cancer, bone diseases, liver and gall diseases, diabetes and the like. The concentration of alkaline phosphatase is the most direct evidence for the diagnosis of related diseases, and is helpful for tracking the clinical treatment effect, and is convenient for the alleviation and treatment of the disease. Therefore, the realization of high-sensitivity detection of the alkaline phosphatase marker has extremely important significance for establishing a precise health condition assessment system, preventing diseases, early warning, diagnosing and the like.
The existing detection methods for alkaline phosphatase mainly comprise an electrochemical method, a surface enhanced Raman spectroscopy method, a fluorescence analysis method and the like. Among them, the fluorescence analysis method is widely used because of its advantages of low requirement on instruments, simple operation, high sensitivity, good selectivity, etc. However, the problems of poor photochemical stability, high toxicity, high cost, long time consumption and the like of organic dyes, quantum dots, metal organic framework materials and the like used in the traditional fluorescence analysis method cannot be avoided, and the method cannot realize the rapid and accurate direct detection of the concentration of alkaline phosphatase.
Compared with traditional organic dyes, quantum dots, metal organic frame materials and the like, the rare earth down-conversion luminescent material has the unique advantage of long-life fluorescence emission, so that the short-life nonspecific fluorescence and stray light interference from the inside of a sample to be detected and an instrument can be effectively removed by controlling proper delay time and data acquisition time. In addition, the rare earth down-conversion luminescence spectrum band is narrow, which is helpful for reducing background and improving resolution; the emission spectrum is positioned in the visible light region, and the intensity of emitted light can be directly observed by naked eyes; the fluorescent dye has excellent stability, can be stored for standby for a long time, and overcomes the problems of organic dye photobleaching, quantum dot photoflash and the like. Many advantages make the rare earth fluorescent probe very suitable for directly detecting the concentration of alkaline phosphatase in a complex biological system. The fluorescent detection method based on rare earth resonance energy transfer is developed and used for accurately detecting the alkaline phosphatase level in a complex system, achieves the purpose of convenient, accurate and economic detection, and is important and significant in the invention.
Disclosure of Invention
In order to improve the above problems, the present invention provides a rare earth metal-based enzyme-responsive probe comprising a rare earth metal ion group and a phospholipid molecule.
According to an embodiment of the present invention, the rare earth metal ion group may be an ion group composed of two or more rare earth ions selected from lanthanum (La), cerium (Ce), praseodymium (Pr), neodymium (Nd), promethium (Pm), samarium (Sm), europium (Eu), gadolinium (Gd), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), thulium (Tm), ytterbium (Yb), lutetium (Lu), yttrium (Y), and scandium (Sc); such as cerium-terbium (Ce-Tb), cerium-europium (Ce-Eu), cerium-dysprosium (Ce-Dy), terbium-europium (Tb-Eu), cerium-neodymium (Ce-Nd), cerium-gadolinium (Ce-Gd), cerium-erbium (Ce-Er), gadolinium-europium (Gd-Eu), gadolinium-terbium (Gd-Tb), gadolinium-dysprosium (Gd-Dy), gadolinium-terbium-europium (Gd-Tb-Eu) or cerium-ytterbium-erbium (Ce-Yb-Er) ion groups, preferably cerium-terbium ion groups.
According to an embodiment of the present invention, the phospholipid molecule may be a phospholipid bond-containing molecule, and the phospholipid bond-containing molecule may be one, two or more of Adenosine Triphosphate (ATP), adenosine Diphosphate (ADP), adenosine Monophosphate (AMP), guanosine Triphosphate (GTP), guanosine Diphosphate (GDP), guanosine Monophosphate (GMP), and ATP is exemplified.
The invention provides a preparation method of the rare earth metal-based enzyme response probe, which comprises the following steps:
1) Dissolving a combination of rare earth metal salts in a buffer solution to prepare a rare earth ion solution;
2) Dissolving phospholipid molecules in a buffer solution to prepare a phospholipid molecule solution;
3) Mixing the rare earth ion solution in the step 1) with the phospholipid molecule solution in the step (2) to obtain the rare earth metal-based enzyme response probe.
According to the present invention, in step 1), the combination of rare earth metal salts may be a combination of two or more rare earth metal salts capable of providing the above-mentioned rare earth ion group; the rare earth metal salt may be nitrate, chloride, acetate, sulfate, perchlorate, or salt hydrate thereof, etc. of lanthanum, cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, ytterbium, lutetium, yttrium, or scandium. For example, the rare earth metal salt may be a trivalent nitrate of a rare earth metal or a hydrate thereof (e.g., hexahydrate, pentahydrate, tetrahydrate, tri-hydrate, dihydrate, monohydrate, etc.), such as Ce (NO 3 ) 3 Or a hydrate thereof (e.g. Ce (NO) 3 ) 3 ·6H 2 O)、Tb(NO 3 ) 3 Or a hydrate thereof (e.g. Tb (NO) 3 ) 3 ·6H 2 O)、La(NO 3 ) 3 、Pr(NO 3 ) 3 、Nd(NO 3 ) 3 、Sm(NO 3 ) 3 、Eu(NO 3 ) 3 、Gd(NO 3 ) 3 、Yb(NO 3 ) 3 Etc.; chlorides of rare earth metals or their hydrates (e.g. heptahydrate, hexahydrate, pentahydrate, tetrahydrate, trihydrate, dihydrate, monohydrate, etc.), e.g. LaCl 3 Or a hydrate thereof (e.g. LaCl) 3 ·7H 2 O)、CeCl 3 Or a hydrate thereof (e.g. CeCl) 3 ·7H 2 O)、PrCl 3 Or a hydrate thereof (e.g. PrCl 3 ·6H 2 O)、TbCl 3 Or a hydrate thereof (e.g. TbCl 3 ·6H 2 O)、DyCl 3 Or a hydrate thereof (e.g. DyCl) 3 ·6H 2 O); can be sulfate or its hydrate (such as heptahydrate, hexahydrate, pentahydrate, tetrahydrate, trihydrate, dihydrate, monohydrate, etc.), such as Y (SO) 4 ) 2 Or a hydrate thereof, ti (SO) 4 ) 2 Or a hydrate thereof, ce (SO) 4 ) 2 Or a hydrate thereof (e.g. Ce (SO) 4 ) 2 ·4H 2 O), and the like.
According to the invention, in step 1), the total concentration of the rare earth ion solution may be 0.5-32mM; for example, 1-30mM,1.5-28mM,2-25mM,2.5-20mM,3-18mM, for example, 1mM, 2mM, 3mM, 4mM, 5mM, 6mM, 7mM, 8mM, 9mM, 10mM, 11mM, 12mM, 13mM, 14mM, 15mM, 16mM, 17mM.
In the context of the present invention, the "total concentration of rare earth metal ion solution" refers to the sum of the concentrations of two or more rare earth ions present in the solution. For example, when the rare earth metal-based enzyme-responsive probe employs a cerium-terbium ion group, the total concentration of the rare earth metal ion solution refers to Ce present in the solution 3+ And Tb 3+ The sum of the concentrations of the ions.
According to the present invention, in step 1), when the rare earth metal-based enzyme-responsive probe employs an ion group composed of two rare earth ions, such as cerium-terbium (Ce-Tb), cerium-europium (Ce-Eu), cerium-dysprosium (Ce-Dy), terbium-europium (Tb-Eu), cerium-neodymium (Ce-Nd), cerium-gadolinium (Ce-Gd), cerium-erbium (Ce-Er), gadolinium-europium (Gd-Eu), gadolinium-terbium (Gd-Tb), gadolinium-dysprosium (Gd-Dy), the molar ratio of the two rare earth ions in the rare earth ion solution, that is, the molar ratio of the former rare earth ion to the latter rare earth ion in the ion group may be 1:10 to 10:1; for example, 1:9-9:1,1:8-8:1,1:7-7:1,1:6-6:1,1:5-5:1,1:4-4:1, e.g., 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1; specifically, ce 3+ And Tb 3+ May be in a molar ratio of 1:10 to 10:1; for example, 1:9-9:1,1:8-8:1,1:7-7:1,1:6-6:1,1:5-5:1,1:4-4:1, for example, 1:10, 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1. When the rare earth metal-based enzyme-responsive probe employs an ion group composed of three rare earth ions, such as gadolinium-terbium-europium (Gd-Tb-Eu) or cerium-ytterbium-erbium (Ce-Yb-Er) ion group, the molar ratio of the three rare earth ions in the rare earth ion solution, i.e., the molar ratio of the former rare earth ion to the intermediate rare earth ion to the latter rare earth ion, may be (1-10): 10-1): 1-10, for example, (1-9): 9-1): 1-9, (1-8): 8-1): 1-8, (1-7): 7-1): 1-7,(1-6): (6-1): (1-6), (1-5): (5-1): (1-5), (1-4): (4-1): (1-4), (1-3): (3-1): (1-3), such as 1:1:1,1:2:1,2:1:1,1:1:2.
According to the present invention, in step 2), the buffer solution may be N-methyl-D-glucosamine (MEG) buffer, 2-amino-2-methyl-1-propanol (AMP) buffer, tris-HCl buffer; exemplary is Tris-HCl buffer; the pH of the buffer may be 7.0-9.0, preferably pH 9.0.
According to the invention, in step 2), the concentration of the phospholipid molecule solution may be 0.5-32mM; for example, 1-30mM,1.5-28mM,2-25mM, e.g., 1mM, 2mM, 3mM, 4mM, 5mM, 6mM, 7mM, 8mM, 9mM, 10mM, 11mM, 12mM, 13mM, 14mM, 15mM, 16mM, 17mM.
According to the invention, the solvent used to formulate the solution in step 1) and step 2) may be water.
According to the present invention, in step 3), the volume ratio of the rare earth ion solution to the phospholipid molecule solution may be 1:5 to 5:1; for example, 1:4-4:1, 1:3-3:1, 1:2-2:1, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1.
The invention provides the use of the rare earth metal-based enzyme-responsive probes for the detection of alkaline phosphatase.
The invention also provides an alkaline phosphatase detection method, which comprises the following steps:
1) Mixing the rare earth metal-based enzyme response probe with a buffer solution to obtain a probe solution;
2) Mixing alkaline phosphatase with a buffer solution to obtain an alkaline phosphatase solution;
3) Mixing the probe solution in the step 1) with the alkaline phosphatase solution in the step 2), oscillating at constant temperature, measuring the fluorescence intensity of the alkaline phosphatase in the sample to be measured, and calculating the concentration of the alkaline phosphatase in the sample to be measured according to a standard curve;
according to an embodiment of the invention, the temperature of the constant temperature oscillation may be 25-40 ℃, for example 30-39 ℃,35-38 ℃,37 ℃; the time of the constant temperature oscillation may be 0.5 to 5 hours, for example 3 hours.
According to an embodiment of the invention, in step 1), the concentration of the probe solution is selected from 0.5-32mM; for example, 1-30mM,1.5-28mM,2-25mM, e.g., 1mM, 2mM, 3mM, 4mM, 5mM, 6mM, 7mM, 8mM, 9mM, 10mM, 11mM, 12mM, 13mM, 14mM, 15mM, 16mM, 17mM.
According to the invention, in step 2), the alkaline phosphatase solution may have a concentration of 0-5000U/L; for example 3000, 2500, 2000, 1500, 1250, 1000, 750, 500, 250, 125, 62.50, 31.25, 15.63, 7.81, 0U/L;
in the present invention, the "cerium-terbium" ion group is exemplified as Ce which allows transition with f-d electric dipole by being coordinated to phospholipid molecules to draw a distance from each other 3+ As a sensitizing ion, tb is sensitized 3+ Realizes the high-efficiency energy transfer process from cerium ion to terbium ion. In the sensitization of ion Ce 3+ Ce by cross relaxation under excitation of excitation light of (c) 3+ Transmitting energy to Tb 3+ Make Tb 3+ Non-radiative transition of high level electrons to 5 D 4 Thereby respectively radiating and transitioning to 7 F 6 , 7 F 5 , 7 F 4 Make Tb 3+ The fluorescence emission signal of (2) is significantly enhanced. Further studies have found that the presence of alkaline phosphatase can effectively cleave the phospholipid bond in ATP, thereby causing the cerium-terbium distance in the probe to become distant, resulting in fluorescence quenching. The content of alkaline phosphatase is positively correlated with the fluorescence quenching effect, so that qualitative and quantitative detection of alkaline phosphatase can be achieved by the probe by utilizing the property.
Advantageous effects
The rare earth metal-based enzyme response probe has the following technical effects:
(1) The probe designed by the invention can effectively shorten the energy transmission distance between the rare earth sensitized ions and the rare earth activated ions by utilizing the strong coordination effect between phospholipid molecules and the rare earth ions, thereby realizing the effective enhancement of the luminescence of the rare earth activated ions. The probe has excellent enzyme response of fluorescent signals and can effectively improve detection sensitivity.
(2) Compared with the traditional fluorescence analysis method, the detection method of the probe design of the invention avoids the defects of high cost, low stability, high toxicity and the like of materials such as organic dye, quantum dot, metal organic framework and the like, realizes the detection of the object to be detected by the probe formed by phospholipid molecules and rare earth ions, and has the advantages of environmental protection, low cost and the like.
(3) The invention overcomes the interference of background fluorescence, stray light and the like in a biological complex system by utilizing the long fluorescence lifetime characteristic of rare earth ions, can be used for detecting alkaline phosphatase or phospholipid related substances, further realizes the detection of the alkaline phosphatase or phospholipid related substances in serum or whole blood samples, has the advantages of simple operation, good anti-interference performance, rapidness, sensitivity, low cost, wide application range and the like, can provide theoretical basis and technical support for real-time monitoring of enzyme disease markers in the complex biological system, and has a certain clinical application prospect.
Drawings
FIG. 1 is a schematic diagram of the principle of the enzyme-responsive rare earth metal probe for ALP detection;
FIG. 2 shows the physicochemical characterization result of the enzyme-responsive probe of preparation example 1;
FIG. 3 shows the ALP concentration-dependent response curves of (a) fluorescence spectra and (b) fluorescence intensities of the mixed solution after the addition of alkaline phosphatase at different concentrations as described in example 1;
FIG. 4 shows the results of the specificity verification of alkaline phosphatase by the enzyme-responsive probes described in example 3;
FIG. 5 shows the detection of alkaline phosphatase in serum as described in example 3: (a) fluorescence contrast in serum steady state and time resolution mode, (b) fluorescence spectrum of mixed solution after adding alkaline phosphatase with different concentrations, and (c) and (d) ALP concentration dependent response curve of fluorescence intensity;
FIG. 6 shows the result of comparing the fluorescence intensity of the dual-ion probe of preparation example 1 with that of the single-ion probe of control preparation example.
Terminology and definitions
"phospholipid bond" in the present invention means phosphoric acid H 3 PO 4 A chemical bond formed after one, two or three hydroxyl groups are removed and hydrogen on the hydroxyl groups are removed from one, two or more phosphoric acid molecules or other hydroxyl-containing molecules; the hydroxyl-containing molecule may be adenosine, guanosine, uridine, xanthosine, inosine, cytidine, thymidine.
"phospholipid molecule" in the present invention means a molecule comprising a phospholipid linkage, which may be a phosphoglycoside comprising a phospholipid linkage, which may be Adenosine Triphosphate (ATP), adenosine Diphosphate (ADP), adenosine Monophosphate (AMP), guanosine Triphosphate (GTP), guanosine Diphosphate (GDP), guanosine Monophosphate (GMP).
Detailed Description
The invention is described in further detail below with reference to the drawings and examples. It should be understood that the scope of the present invention is not limited to the following examples. Various changes and modifications to the present invention will become apparent to those skilled in the art upon reading the disclosure herein, and such equivalents are intended to fall within the scope of the invention as defined by the appended claims.
Unless otherwise indicated, the starting materials or reagents employed in the examples were all commercially available or may be prepared by known methods.
Instrument: the model of the apparatus for detecting the transmission electron microscope image is JEM-2010 manufactured by JEOL company; the instrument for detecting the fluorescent signal is a fluorescent enzyme-labeled instrument with the model number of Synergy 4 manufactured by BioTek company.
Preparation example 1: synthesis of rare earth metal-based enzyme-responsive probes (zwitterionic probes)
The probe is prepared by a room temperature stirring method, and takes rare earth nitrate and ATP compound as raw materials, and the preparation method is as follows:
(1) The same amount of Ce (NO) was weighed out separately 3 ) 3 ·6H 2 O、Tb(NO 3 ) 3 ·6H 2 O is dissolved in Tris-HCl aqueous solution with pH value of 9.0 to prepare rare earth ion solution with total concentration of rare earth ions of 4 mM;
(2) ATP is weighed and dissolved in Tris-HCl aqueous solution to prepare ATP solution with the concentration of 2mM;
(3) Taking 1mL of the rare earth ion solution in the step (1), uniformly mixing, dripping into 1mL of the ATP solution in the step (2), and stirring at room temperature for reacting for one minute.
The characterization result of the prepared probe (also called as a double-ion probe) is shown in fig. 2, wherein (a) and (b) are transmission electron microscope images of the double-ion probe; (c) is an XRD diffraction pattern of the dual ion probe; (d) X-ray photoelectron spectroscopy for a dual ion probe; (e) is the infrared absorption spectrum of the double ion probe. From the results, it can be seen that the prepared ATP-Ce/Tb double ion probe has a size of 20-50nm and is in an amorphous state (amorphous state).
Control preparation example: synthesis of rare earth metal-based enzyme-responsive probes (single-ion probes)
Preparation of ATP-Ce single ion probe
(1) Preparation of Ce (NO) at a concentration of 4mM 3 ) 3 ·6H 2 O rare earth ion solution (Tris-HCl, ph=9.0);
(2) ATP is weighed and dissolved in Tris-HCl aqueous solution to prepare ATP solution with the concentration of 2mM;
(3) Slowly dripping 2mL of the rare earth ion solution in the step (1) into 1mL of the ATP solution in the step (2), and stirring at room temperature for reacting for one minute;
(4) Centrifugal cleaning, dispersing the precipitate in ultrapure water again, and preserving at low temperature for standby.
Preparation of ATP-Tb single ion probe
(1) Preparation of Tb (NO) at a concentration of 4mM 3 ) 3 ·6H 2 O rare earth ion solution (Tris-HCl, ph=9.0);
(2) ATP is weighed and dissolved in Tris-HCl aqueous solution to prepare ATP solution with the concentration of 2mM;
(3) Slowly dripping 2mL of the rare earth ion solution in the step (1) into 1mL of the ATP solution in the step (2), and stirring at room temperature for reacting for one minute;
(4) Centrifugal cleaning, dispersing the precipitate in ultrapure water again, and preserving at low temperature for standby.
FIG. 6 shows the fluorescence intensity contrast of a dual ion probe versus a single ion probe. From this figure it is evident that the fluorescence intensity of the ATP-Ce/Tb probe is significantly enhanced compared to that of the single ion probes (ATP-Ce and ATP-Tb). The single ion luminescence is weak, and the double ion system greatly improves the luminescence intensity by using sensitization, so that the double ion system has higher detection sensitivity.
Example 1: detection of alkaline phosphatase concentration
(1) Using polystyrene 96-well plate as carrier, adding 7 rows of 100 μL probe solution prepared in preparation example 1 into the prepared microwells, wherein each row has concentration of 32, 16, 8, 4, 2, 1, 0.5mM, and each row sequentially adds 100 μL alkaline phosphatase (ALP) water solution with different concentration, and the concentration is 3000, 2500, 2000, 1500, 1250, 1000, 750, 500, 250, 125, 62.50, 31.25, 15.63, 7.81, 0U/L; placing the mixture at a constant temperature of 37 ℃ for shaking for 3 hours, respectively measuring the fluorescence intensity of 7 rows and 15 columns of mixed solutions, and calculating the fluorescence quenching efficiency of each group of mixed solutions; the probe concentration corresponding to the mixed solution was 4mM when the fluorescence quenching efficiency was maximized, and Tb was measured by the concentration of alkaline phosphatase in the mixed solution 3+ The concentration-dependent curve of alkaline phosphatase can be obtained by plotting the fluorescence intensity of (a) as shown in FIG. 3.
FIG. 3a shows that the detection system established by the invention has response to alkaline phosphatase in a certain concentration range, and the higher the concentration of alkaline phosphatase is, the weaker the fluorescence intensity of the corresponding mixed liquor is. FIG. 3b shows that the fluorescence intensity shows a good linear relationship with the concentration of alkaline phosphatase in a certain concentration range.
The results of FIGS. 3a and 3b show that the detection method of the present embodiment can realize the detection of the alkaline phosphatase concentration.
Example 2: assay specificity verification for alkaline phosphatase to be assayed
(1) Reagents, instruments, probes required for the experiment were as in example 1.
(2) The experiment selects common interferents in blood: arginine, glycine, biotin, citric acid, lactose, bovine Serum Albumin (BSA), glucose Oxidase (GOD), cholinesterase, metal ion (K) + 、Ca 2+ 、Cl - 、Na + 、Mg 2+ )。
(3) After the detection well plates were set in groups in the 96 well plates, 100. Mu.L of the above-mentioned aqueous solution of the interfering substance at a concentration of 100mg/mL and 100. Mu.L of the aqueous solution of alkaline phosphatase at a concentration of 100U/L were added to 100. Mu.L of Tris-HCl buffer solution of pH=9.0 containing a probe (final concentration of 4 mM), the 96 well plates were subjected to a constant temperature shaking reaction at 37℃for 3 hours, and the fluorescence intensities of the respective groups of mixed solutions were measured in an enzyme-labeled instrument, with the corresponding fluorescence intensity values shown in FIG. 4.
As can be seen from the bar graph of FIG. 4, only alkaline phosphatase is capable of significantly quenching fluorescence, while the influence of the rest of interferents on fluorescence intensity is insignificant, indicating that the probe has good specificity for alkaline phosphatase detection, and the influence of the interferents can be avoided in practical detection.
Example 3: investigation of alkaline phosphatase recovery in Complex System samples
1. The 96-well plate settings and instruments required for the experiment were the same as in example 1, and the probe solutions required for the experiment were the same as in example 1.
2. The model matrix for complex system detection is a serum and whole blood sample of a healthy person.
For the detection of alkaline phosphatase concentration in serum or whole blood samples, the feasibility of the alkaline phosphatase concentration is verified by using a labeling recovery rate experiment, and the specific operation steps are as follows:
taking two healthy human serum samples and one healthy human whole blood sample (in which alkaline phosphatase has been inactivated) subjected to protein inactivation by high temperature treatment, diluting both the serum samples and the whole blood sample 50 times with Tris-HCl buffer solution (ph=9.0), and adding a certain amount of alkaline phosphatase to each as a matrix; to the preset microwells, 100. Mu.L of a probe solution having a concentration of 4mM was added, 50. Mu.L of an alkaline phosphatase solution diluted with a serum sample and a whole blood sample was added, and then the solution to be tested was fixed to a volume of 200. Mu.L with a Tris-HCl buffer solution (pH=9.0). The concentration of the probe in each of the mixed solutions was 2mM, and the alkaline phosphatase concentrations were 50U/L, 100U/L and 200U/L, respectively. After the reaction is carried out for 3 hours at the constant temperature of 37 ℃, the mixture is placed in an enzyme-labeled instrument to measure the fluorescence intensity of the mixed liquid at 550nm, and then the standard curve is substituted to calculate the alkaline phosphatase content after the serum and the whole blood sample are added, and the sample adding recovery rate is calculated. The specific results are shown in Table 1 in detail, and the results show that the sample recovery rate values of the serum sample and the whole blood sample are in a reasonable range, so that the detection system of the embodiment has good precision and reproducibility.
TABLE 1 detection results of alkaline phosphatase in example 3
Claims (11)
1. Use of a rare earth metal-based enzyme-responsive probe for detecting alkaline phosphatase, the probe comprising a rare earth metal ion group and a phospholipid molecule;
the rare earth metal ion group is a cerium-terbium ion group;
the phospholipid molecule is a molecule containing a phospholipid bond, and the molecule containing a phospholipid bond is one, two or more of Adenosine Triphosphate (ATP), adenosine Diphosphate (ADP), adenosine Monophosphate (AMP), guanosine Triphosphate (GTP), guanosine Diphosphate (GDP) and Guanosine Monophosphate (GMP);
the use is not for the diagnosis and/or treatment of diseases.
2. The use according to claim 1, wherein the method for preparing the enzyme-responsive probe comprises:
1) Dissolving a combination of rare earth metal salts in a buffer solution to prepare a rare earth ion solution;
2) Dissolving phospholipid molecules in a buffer solution to prepare a phospholipid molecule solution;
3) Mixing the rare earth ion solution in the step 1) with the phospholipid molecule solution in the step (2) to obtain the rare earth metal-based enzyme response probe.
3. Use according to claim 2, characterized in that in step 1) the rare earth metal salt is a nitrate, chloride, acetate, sulfate, perchlorate or its salt hydrate of cerium, terbium.
4. The use according to claim 2, wherein in step 1) the total concentration of the rare earth ion solution is between 0.5 and 32 and mM.
5. The use according to claim 2, wherein in step 1), when the rare earth metal-based enzyme-responsive probe employs an ion set of two rare earth ions, the molar ratio of the two rare earth ions in the rare earth ion solution is 1:10-10:1.
6. The use according to claim 2, wherein in step 2) the buffer solution is N-methyl-D-glucamine (MEG) buffer, 2-amino-2-methyl-1-propanol (AMP) buffer, tris-hydroxymethyl aminomethane-hydrochloric acid (Tris-HCl) buffer; the pH of the buffer is 7.0-9.0.
7. The use according to claim 2, wherein in step 2) the concentration of the phospholipid molecule solution is between 0.5 and 32 and mM.
8. The use according to claim 2, wherein the solvent used for the preparation of the solution in step 1) and step 2) is water.
9. The use according to claim 2, characterized in that in step 3) the rare earth ion solution is mixed with the phospholipid molecule solution in a volume ratio of 1:5-5:1.
10. A method for detecting alkaline phosphatase, comprising the steps of:
1) Mixing the probe in the use according to any one of claims 1-9 with a buffer to obtain a probe solution;
2) Mixing alkaline phosphatase with a buffer solution to obtain an alkaline phosphatase solution;
3) Mixing the probe solution in the step 1) with the alkaline phosphatase solution in the step 2), oscillating at constant temperature, measuring the fluorescence intensity of the alkaline phosphatase in the sample to be measured, and calculating the concentration of the alkaline phosphatase in the sample to be measured according to a standard curve;
the detection method is not aimed at diagnosis and/or treatment of the disease.
11. The method according to claim 10, wherein the temperature of the constant temperature oscillation is 25-40 ℃;
and/or, in step 1), the concentration of the probe solution is selected from 0.5-32mM;
and/or, in the step 2), the concentration of the alkaline phosphatase solution is 0-5000U/L.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010140295.8A CN113354703B (en) | 2020-03-03 | 2020-03-03 | Rare earth metal-based enzyme response type probe and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010140295.8A CN113354703B (en) | 2020-03-03 | 2020-03-03 | Rare earth metal-based enzyme response type probe and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113354703A CN113354703A (en) | 2021-09-07 |
CN113354703B true CN113354703B (en) | 2024-02-23 |
Family
ID=77523147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010140295.8A Active CN113354703B (en) | 2020-03-03 | 2020-03-03 | Rare earth metal-based enzyme response type probe and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113354703B (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010055207A1 (en) * | 2008-11-17 | 2010-05-20 | Wallac Oy | Chelating, chelating agents and conjugates deriver thereof |
CN104961754A (en) * | 2015-04-09 | 2015-10-07 | 江西师范大学 | Method for preparing red luminous guanylic acid/rare earth coordination polymer based on energy transfer principle |
CN105949473A (en) * | 2016-05-16 | 2016-09-21 | 南昌大学 | Preparation method of rare-earth coordination polymer fluorescence probe and application of rare-earth coordination polymer fluorescence probe in H2O2 and glucose detection |
CN108249414A (en) * | 2016-12-28 | 2018-07-06 | 浙江美加华医疗技术有限公司 | A kind of rear-earth-doped hydroxyapatite nanoparticle and preparation method thereof |
CN109913527A (en) * | 2019-02-11 | 2019-06-21 | 张丽英 | A method of utilizing shigella dysenteriae in ATP bioluminescence reaction detection food |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2777715A1 (en) * | 2013-03-14 | 2014-09-17 | Centre National de la Recherche Scientifique (CNRS) | Particles comprising luminescent lanthanide complexes |
US11170986B2 (en) * | 2017-10-17 | 2021-11-09 | U.S. Department Of Energy | Luminescence based fiber optic probe for the detection of rare earth elements |
-
2020
- 2020-03-03 CN CN202010140295.8A patent/CN113354703B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010055207A1 (en) * | 2008-11-17 | 2010-05-20 | Wallac Oy | Chelating, chelating agents and conjugates deriver thereof |
CN104961754A (en) * | 2015-04-09 | 2015-10-07 | 江西师范大学 | Method for preparing red luminous guanylic acid/rare earth coordination polymer based on energy transfer principle |
CN105949473A (en) * | 2016-05-16 | 2016-09-21 | 南昌大学 | Preparation method of rare-earth coordination polymer fluorescence probe and application of rare-earth coordination polymer fluorescence probe in H2O2 and glucose detection |
CN108249414A (en) * | 2016-12-28 | 2018-07-06 | 浙江美加华医疗技术有限公司 | A kind of rear-earth-doped hydroxyapatite nanoparticle and preparation method thereof |
CN109913527A (en) * | 2019-02-11 | 2019-06-21 | 张丽英 | A method of utilizing shigella dysenteriae in ATP bioluminescence reaction detection food |
Non-Patent Citations (2)
Title |
---|
张向阳.《医学分子生物学》.江苏凤凰科学技术出版社,2018,(2018年2月第2版),第137-139页. * |
核苷酸/稀土配位荧光探针的制备及其生物检测性能研究;曾慧慧;《中国博士学位论文全文数据库•工程科技I辑》(2017年第04期);B014-65 * |
Also Published As
Publication number | Publication date |
---|---|
CN113354703A (en) | 2021-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106018366B (en) | A kind of fluorescent DNA-silver nanoclusters and preparation method thereof and application | |
Schäferling et al. | Europium tetracycline as a luminescent probe for nucleoside phosphates and its application to the determination of kinase activity | |
Ma et al. | A terbium chelate based fluorescent assay for alkaline phosphatase in biological fluid | |
CN111100476B (en) | Synthesis and application of pH fluorescent probe | |
CN112646191B (en) | Rare earth-organic framework nano fluorescent probe and preparation method and application thereof | |
Wu et al. | Specific circularly polarized luminescence of Eu (III), Sm (III), and Er (III) induced by N-acetylneuraminic acid | |
Cui et al. | A highly selective and sensitive fluorescent sensor based on Tb 3+-functionalized MOFs to determine arginine in urine: A potential application for the diagnosis of cystinuria | |
Sun et al. | Pb (ii) detection and versatile bio-imaging of green-emitting carbon dots with excellent stability and bright fluorescence | |
Lv et al. | Carbon dots doped lanthanide coordination polymers as dual-function fluorescent probe for ratio sensing Fe2+/3+ and ascorbic acid | |
CN112816414B (en) | Alkaline phosphatase detection kit based on dual-emission lanthanide MOF and detection method | |
WO2015106466A1 (en) | Gold/silver fluorescent nanomaterial synthesized rapidly in-situ on basis of biomolecules such as nucleosides, and preparation method and use for said material | |
CN113354703B (en) | Rare earth metal-based enzyme response type probe and preparation method and application thereof | |
CN107417681A (en) | Fluorescent probe compound containing coumarin-thiadiazole Schiff base and preparation method and application thereof | |
Song et al. | A novel ratiometric fluorescence probe based on flower ball-like metal–organic frameworks for detecting carcinoid biomarker in urine | |
Duan et al. | Dual-emission LaF3: Tb@ DPA-Eu nanoparticles as a ratiometric fluorescence probe for the detection of marbofloxacin | |
CN105503768A (en) | Preparation method of alpha-oxoglutarate fluorescent/ultraviolet molecular probe and application of alpha-oxoglutarate fluorescent/ultraviolet molecular probe to biological samples | |
Li et al. | Coordination polymer nanoprobe integrated carbon dot and phenol red for turn-on fluorescence detection of urease activity | |
CN114574192B (en) | Preparation of nuclear shell structure up-conversion nano fluorescence sensing probe and application of nuclear shell structure up-conversion nano fluorescence sensing probe in mesna detection | |
CN113930237B (en) | Modified g-C 3 N 4 @MOF fluorescent composite material and preparation method and application thereof | |
Yegorova et al. | Novel luminescent probe based on a terbium (III) complex for hemoglobin determination | |
Bailey et al. | Rapid spectrofluorimetric determination of plasma salicylate with edta and terbium | |
Yuguang et al. | Research and application of fluorescence system on norfloxacin-terbium-phen-SDBS | |
Pei et al. | A fluorescent probe based on an enhanced ICT effect for Hg 2+ detection and cell imaging | |
Azab et al. | Time-resolved fluorescence sensing of N-acetyl amino acids, nucleobases, nucleotides and DNA by the luminescent Tb (III)-8-alkyl-2-oxo-2H-chromene-3-carbaldehyde probe | |
Yi et al. | Dual-mode detection of 2, 6-pyridinedicarboxylic acid based on the enhanced peroxidase-like activity and fluorescence property of novel Eu-MOFs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |